M. Laguno

J. Mallolas, E. Martinez, J. Blanco, 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients

Á. Soriano, J. Mallolas, M. Laguno, 2022, Infection.

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

J. Gatell, J. Mallolas, E. Martinez, 2014, The Journal of antimicrobial chemotherapy.

Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1–Infected Patients

J. Gatell, J. Mallolas, E. Martinez, 2013, Therapeutic drug monitoring.

Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

A. Mocroft, J. Lundgren, M. Laguno, 2020, Open forum infectious diseases.

Abacavir does not Influence the Rate of Virological Response in HIV–HCV-Coinfected Patients Treated with Pegylated Interferon and Weight-Adjusted Ribavirin

J. Gatell, J. Mallolas, M. Laguno, 2008, Antiviral therapy.

Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C

Felipe García, J. Miro, J. Gatell, 2004, Antiviral therapy.

Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients.

C. Tural, M. Laguno, M. Crespo, 2010 .

Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome

Á. Soriano, J. Miro, J. Mallolas, 2020, International Journal of Infectious Diseases.

Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.

J. Gatell, A. León, J. Mallolas, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Do ART and Chemsex Drugs Get Along? Potential Drug–Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study

L. Miquel, J. Blanch, J. Mallolas, 2022, Infectious Diseases and Therapy.

Direct‐acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda

M. Laguno, P. Aguilera, J. To-Figueras, 2017, The British journal of dermatology.

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study

J. Mallolas, M. Laguno, J. Losa, 2019, PloS one.

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

T. Pumarola, J. Gatell, A. León, 2005, AIDS.

Survival of patients with polymyositis/dermatomyositis and pulmonary involvement.

Ò. Miró, M. Laguno, J. Grau, 1999, The Journal of rheumatology.

Estado actual de la hepatitis aguda C

J. Mallolas, E. Martinez, J. Blanco, 2011 .

Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns

M. Laguno, J. Caylà, J. Navarro, 2017, PloS one.

Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study

X. Forns, J. Blanch, J. Mallolas, 2021, Infectious Diseases and Therapy.

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study.

J. J. de la Cruz, V. Soriano, M. Vogel, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients.

J. Gatell, J. Mallolas, E. Martinez, 2012, AIDS research and human retroviruses.

Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing.

X. Forns, F. González-Candelas, J. Mallolas, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Miguel Ángel Martínez, D. Podzamczer, J. Mallolas, 2021, The Lancet HIV.

Pacemaker-Related Endocarditis

Ò. Miró, A. de la Sierra, M. Laguno, 1999, Cardiology.

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Roger Paredes, Esteban Martinez, Bonaventura Clotet, 2018, The Journal of antimicrobial chemotherapy.

Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.

J. Gatell, J. Sánchez-Tapias, A. León, 2008, AIDS research and human retroviruses.

Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin

J. Gatell, J. Sánchez-Tapias, A. León, 2007, Journal of acquired immune deficiency syndromes.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Felipe García, A. León, J. Mallolas, 2016, The Journal of antimicrobial chemotherapy.

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

J. Mallolas, M. Laguno, S. Mauss, 2004, Hepatology.

[GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)].

J. Miro, M. Laguno, J. Vilardell, 2005, Enfermedades infecciosas y microbiologia clinica.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

A. León, J. Mallolas, E. Martinez, 2004, AIDS.

Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy

X. Forns, M. Laguno, Z. Mariño, 2020, Journal of viral hepatitis.

Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients

Felipe García, J. Miro, J. Gatell, 2005, Antiviral therapy.

Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data

Á. Soriano, J. Mallolas, J. Blanco, 2021, Infectious Diseases and Therapy.

Muscle diseases in elders: a 10-year retrospective study.

Ò. Miró, M. Laguno, J. Grau, 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

Effect of An Induction Period of Pegylated Interferon-α2A and Ribavirin on Early Virological Response in HIV–HCV-Coinfected Patients: Results from the Coral-2 Study

R. Paredes, B. Clotet, C. Tural, 2011, Antiviral therapy.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Felipe García, A. León, J. Mallolas, 2016, The Journal of antimicrobial chemotherapy.

Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations

T. Pumarola, J. Gatell, A. León, 2006, AIDS.

An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide–induced cholestasis

J. Mallolas, M. Laguno, M. Martínez-Rebollar, 2021, Antiviral therapy.

Effects of tobacco smoking on HIV-infected individuals.

E. Martinez, M. Laguno, M. Calvo, 2015, AIDS reviews.

Overview of SARS-CoV-2 infection in adults living with HIV

Á. Soriano, J. Miro, J. Mallolas, 2021, The Lancet HIV.

Liver transplantation in HIV/hepatitis co-infection.

J. Miro, M. Laguno, J. García-Valdecasas, 2007, Journal of HIV therapy.

Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Á. Soriano, M. Laguno, J. Nicolás, 2020, medRxiv.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Tolerability of integrase inhibitors in a real-life setting

J. Gatell, J. Blanch, J. Mallolas, 2017, The Journal of antimicrobial chemotherapy.

Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life—Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain

L. Miquel, J. Blanch, J. Mallolas, 2022, AIDS and Behavior.

Vulnerability Conditions in a Cohort of Men Who Have Sex with Men Who Engage in Chemsex in Barcelona City: a Cross-Sectional Study

L. Miquel, J. Blanch, J. Mallolas, 2022, Sexuality Research and Social Policy.

Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women

J. Mallolas, E. Martinez, J. Blanco, 2011, Therapeutic Drug Monitoring.

Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy

J. Blanco, M. Laguno, J. Bosch, 2009, The American Journal of Gastroenterology.

Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years’ Experience

J. Mallolas, J. Blanco, M. Laguno, 2022, Infectious Diseases and Therapy.

PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement.

J. Mallolas, E. Martinez, J. Blanco, 2021, Enfermedades infecciosas y microbiologia clinica.

Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020

E. Fernández, J. Mallolas, J. Blanco, 2023, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Á. Soriano, J. Mallolas, M. Laguno, 2022, Scientific Reports.

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

D. Podzamczer, J. Miro, D. Giralt, 2021, BMC Public Health.

[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].

J. Gatell, J. Mallolas, E. Martinez, 2015, Enfermedades infecciosas y microbiologia clinica.

Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.

Felipe García, M. Plana, T. Gallart, 2008, The Journal of antimicrobial chemotherapy.

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor

Felipe García, M. Arnedo, T. Pumarola, 2005, AIDS.

A 24-week pilot study of dual maintenance therapy with raltegravir plus lamivudine.

M. Plana, J. Blanch, J. Mallolas, 2019, AIDS.

Impact of Prior Virological Failure and Nucleos(t)ide Genotypic Resistance Mutations on the Efficacy of Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir

D. Podzamczer, J. Mallolas, E. Martinez, 2015, Antiviral therapy.

Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study

Á. Soriano, M. Laguno, I. Alobid, 2021, BMJ Open.

Ò. Miró, A. de la Sierra, M. Laguno, 1998, Cardiology.

Noninvasive Diagnosis of Hepatic Fibrosis in HIV/HCV-Coinfected Patients

J. Miro, J. Gatell, A. León, 2007, Journal of acquired immune deficiency syndromes.

IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.

J. Miro, A. Forner, M. Laguno, 2016, The Journal of antimicrobial chemotherapy.

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.

A. Cruceta, J. Mallolas, M. Laguno, 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital

M. Laguno, P. Aguilera, J. To-Figueras, 2016, Photodermatology, photoimmunology & photomedicine.

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

D. Podzamczer, J. Blanco, M. Laguno, 2020, Clinical Microbiology and Infection.

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

A. Borobia, D. Podzamczer, Á. Soriano, 2021, The Lancet. Infectious diseases.

[Clinical course of idiopathic inflammatory myopathies: complications, survival and prognostic factors].

Ò. Miró, M. Laguno, J. Grau, 1999, Medicina clinica.

Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV‐RNA viraemia and HIV coinfection

J. Yagüe, X. Forns, M. Laguno, 2007, Journal of Viral Hepatitis.

Experience with the use of siltuximab in patients with SARS-CoV-2 infection

Á. Soriano, M. Laguno, M. Bodro, 2021, Revista Española de Quimioterapia.

Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Felipe García, Á. Soriano, M. Laguno, 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients.

Felipe García, M. Plana, T. Gallart, 2007, AIDS research and human retroviruses.

Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.

J. Mallolas, M. Laguno, M. Londoño, 2019, Gastroenterologia y hepatologia.

Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia

J. Mallolas, M. Laguno, M. Londoño, 2019, Gastroenterología y Hepatología (English Edition).

Impact of coronavirus disease 2019 epidemics on prevention and care for HIV and other sexually transmitted infections

J. Miro, J. Mallolas, E. Martinez, 2022, AIDS.

Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants

M. Arnedo, J. Mallolas, M. Laguno, 2012, PloS one.

The model for end‐stage liver disease score is the best prognostic factor in human immunodeficiency virus 1–infected patients with end‐stage liver disease: A prospective cohort study

J. Miro, J. Blanco, M. Laguno, 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection.

J. Gatell, J. Mallolas, M. Laguno, 2005, AIDS.

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct‐acting antivirals—Results from the EuroSIDA study

C. Leen, A. Mocroft, A. Winston, 2022, HIV medicine.

Increasing of New CA-MRSA Infections Detected in people living with HIV Who Engage in Chemsex in Barcelona: An Ambispective Study

Á. Soriano, J. Mallolas, J. Blanco, 2023, Infectious Diseases and Therapy.

Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.

J. Mallolas, J. Blanco, M. Laguno, 2023, The Journal of antimicrobial chemotherapy.

Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy.

M. Laguno, L. Tarancón-Díez, S. Jiménez de Ory, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation

J. Sterne, J. Rockstroh, D. Neau, 2023, AIDS.

Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area

A. León, J. Mallolas, M. Laguno, 2007, HIV medicine.

Differences between HIV‐infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case–control studies

J. Mallolas, M. Laguno, M. Junyent, 2013, HIV medicine.

Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients [abstract LB-37]

J. Mallolas, M. Laguno, J. Slim, 2012 .

Experience with the use of siltuximab in patients with SARS-CoV-2 infection

Á. Soriano, M. Laguno, M. Bodro, 2021, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Relapses in idiopathic inflammatory myopathies

M. Laguno, J. Grau, Ò. Miró, 1999, Muscle & nerve.

Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.

J. Mallolas, M. Laguno, J. Ambrosioni, 2023, The Journal of antimicrobial chemotherapy.

Perception of quality of care using patient reported experience measures (PREMs) in a cohort of adults with HIV: A cross-sectional study

J. Miro, E. Fernández, J. Mallolas, 2022, Medicine.